This review reveals eosinophils' varied roles in type 1 and type 2 immunity, highlighting survival and mobilization mechanisms in tissue environments.
Eosinophils have traditionally been viewed as terminally differentiated type 2 effector cells involved in anti-helminth immunity and allergic inflammation. Recent advances in single-cell transcriptomics have refined this view, revealing substantial developmental and functional heterogeneity across tissues and inflammatory settings. Eosinophil development in the bone marrow is controlled by lineage-defining transcription factors and by cytokines such as IL-5, IL-3, GM-CSF and IL-33, which regulate progenitor expansion, maturation, mobilization and survival. After entering tissues, eosinophils integrate local cytokine, stromal, epithelial, microbial and metabolic signals to acquire context-dependent activation states. In this review, we summarize core developmental programs of eosinophils and examine how cytokine networks shape their responses across type 1, type 2 and type 17 immunity. We discuss evidence that eosinophils contribute not only to classical type 2 responses, but also to antimicrobial, cytotoxic, immunoregulatory and tissue-remodeling programs in non-type 2 settings, positioning them as highly plastic effectors with broad roles in host defense, tissue homeostasis and disease.
No takes yet. Share an insight, caveat, or question.
King et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: